|
[1]
|
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1789-1858.
|
|
[2]
|
王乐乐, 杨松, 唐神结. 治疗性药物监测在结核病治疗中的应用进展[J]. 中国防痨杂志, 2021, 43(3): 285-290.
|
|
[3]
|
Bozorg, B.D., Goodarzi, A., Fahimi, F., et al. (2019) Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-Performance Liquid Chromatography and UV Detection. Iranian Journal of Pharmaceutical Research, 18, 1735-1741.
|
|
[4]
|
张亮, 钱智磊, 陆磊, 等. 同时测定血浆INH、AcINH、RFP和PZA的高效液相色谱法建立及其在肺结核患者中的应用[J]. 山东医药, 2015, 55(48): 23-26.
|
|
[5]
|
张瑞雨, 师真, 李文廷, 等. UPLC-MS/MS同时测定结核患者体内异烟肼、利福平的浓度[J]. 中国药学杂志, 2019, 54(5): 407-410.
|
|
[6]
|
Saras-Nacenta, M., López-Púa, Y., Lípez-Cortés, L.F., et al. (2001) Determination of Efavirenz in Human Plasma by High-Performance Liq-uid Chromatography with Ultraviolet Detection. Journal of Chromatography B: Biomedical Sciences and Applications, 763, 53-59. [Google Scholar] [CrossRef]
|
|
[7]
|
Fox, D., O’Connor, R., Mallon, P., et al. (2011) Simultaneous Determination of Efavirenz, Rifampicin and Its Metabolite Desacetyl Rifampicin Levels in Human Plasma. Journal of Pharmaceutical and Biomedical Analysis, 56, 785-791. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Sailaja, A.L., Kumar, K.K., Kumar, D.V.R.R., et al. (2007) Devel-opment and Validation of a Liquid Chromatographic Method for Determination of Efavirenz in Human Plasma. Chro-matographia, 65, 359-361. [Google Scholar] [CrossRef]
|
|
[9]
|
Ramachandran, G., Kumar, A.K.H., Swaminathan, S., et al. (2009) Simple and Rapid Liquid Chromatography Method for Determination of Efavirenz in Plasma. Journal of Chromatog-raphy B, 879, 3663-3667. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Le Guellec, C., Gaudet, M.L., Lamanetre, S., et al. (1997) Sta-bility of Rifampin in Plasma: Consequences for Therapeutic Monitoring and Pharmacokinetic Studies. Therapeutic Drug Monitoring, 19, 669-674. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
荆颖, 黄淑萍, 王倩, 张洁. 利福平药动学影响因素的研究进展[J]. 中国药房, 2017, 28(12): 1726-1728.
|